A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis

发表于 4 天前

期刊：British Journal of Dermatology

文献作者：Lin Cai; Congjun Jiang; Guoqiang Zhang; Hong Fang; Jinyan Wang; Yumei Li; Hui Xu; Rong Xiao; Yangfeng Ding; Kun Huang; Chunlei Zhang; Litao Zhang; Bin Chen; Xinsuo Duan; Weili Pan; Guangming Han; Rongyi Chen; Lunfei Liu; Shoumin Zhang; Juan Tao; Xiaowen Pang; Jianbin Yu; Huiping Wang; Yi Zhao; Chengxin Li; Xiaojing Kang; Lanying Qin; Xiaofang Zhu; Juan Su; Shanshan Li; Chunjun Yang; Wenli Feng; Tiechi Lei; Shan Jiang; Ruihua Fang; Mao Lin; Qianjin Lu; Chunxing Xu; Wei Wang; Jianzhong Zhang

出版日期：2024-8-14

DOI号：10.1093/bjd/ljae062

下载链接：https://academic.oup.com/bjd/adv ... 8346402/ljae062.pdf

文献链接：https://doi.org/10.1093/bjd/ljae062

当前文献来源于 Oxford University Press (OUP)。

备注信息：

[oxford] A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis

发表回复

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[oxford] A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis 一键复制